[ad_1]
A new treatment against antibiotic-resistant tuberculosis, one of the deadliest, achieved a 90% success rate according to clinical trials to which AFP had access on Monday. [[19659002] A medical team from Belarus (one of the countries where the disease is most prevalent) has tried for several months to badociate badaquiline with other antibiotics, 181 patients and has cured 168, according to the study.
The results are as follows: clear: out of 181 patients, 168 are completely cured.
According to the World Health Organization (WHO), only 55% of people with multidrug-resistant TB can be cured.
The success of the Belarusian study (93%) could be resumed in other clinical trials on badaquiline in Eastern Europe, Africa and Southeast Asia, according to the conclusions consulted by AFP that will be presented this week at a meeting. A summit dedicated to tuberculosis.
"The results of this study confirm (…) that new treatments such as badaquiline can cure and are good news for people with multidrug-resistant TB or Dr. Paula I Fujiwara , Scientific Director of the International Union Against Tuberculosis and Lung Disease (IUATLD), which is not related to this study, told AFP.
Tuberculosis, a disease transmitted by Respiratory route, has killed 1.7 million people in 2017, according to the WHO, making it the most deadly communicable disease in the world when it 's all about. a disease that can be prevented, treated and cured.
However, the attention and money of donors are focused on AIDS.
A study published in the medical journal The Lancet in 2017 considers By 2040, 12.4% of TB cases would be caused by strains resistant to antibiotics.
According to the WHO, multidrug-resistant TB strains were registered in at least 117 countries.
Tuberculosis is caused by a bacterium that most commonly affects the lungs, as well as the kidneys, ganglia and bones.
[ad_2]
Source link
